Arthritis Clinical Trials in Baltimore
View 32 new treatments for Arthritis in Baltimore, MD. Every day, Power helps hundreds of Arthritis patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Oritavancin + Medication for Infections and Opioid Use Disorder
Research Clinic, Baltimore + 1 more
Standard of care for patients with opioid use disorder and complicated infections is discharge to subacute nursing facilities on IV antibiotics until completion of treatment course. We aim to determine the efficacy of an alternative strategy using intermittent outpatient oritavancin therapy dosed weekly combined with initiation and continuation of medication assisted treatment for opioid use disorder for completion of antimicrobial therapy in a 12 week prospective, open-label study. Patients hospitalized for a drug use related infection and thought to need prolonged parenteral antimicrobial therapy will be assessed by a substance use consultant and Infectious Diseases service. If they are not on Medication for Opioid Use Disorder (MOUD), they will be assessed for initiation of MOUD. A collaborative multidisciplinary discharge planning process will be initiated and will involve linkage to care. If they have an infection with a gram positive organism, and are thought to be clinically stable for hospital discharge, they will be assessed for appropriateness for oritavancin and first dose will be administered prior to discharge. They will have an intake into an opioid treatment program where they can access collocated services and will be discharged with linkage to care through a peer recovery coach. They will be assessed in this collocated clinic post discharge for optimization of MOUD and progress of infection and subsequent dose/s of oritavancin will be administered. Patients will be followed for 12 weeks for cure/completion of therapy and MOUD outcomes.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team
Baricitinib vs TNF Inhibitors for Rheumatoid Arthritis
Eli Lilly Clinic, Wheaton + 1 more
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.Show More
Waitlist
No Placebo Trial
Phase 4
Est. 3 - 6 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Stopping TNF Inhibitors for Rheumatoid Arthritis
Research Clinic, Bethesda + 1 more
Background: * Rheumatoid arthritis (RA) is often treated with drugs known as tumor necrosis factor (TNF) inhibitors, that can help decrease joint pain and swelling and can even result in RA remission. However, TNF inhibitors may increase risk of serious infections or some types of cancer. * It is not clear if people whose RA has been in remission for a long time need to stay on the TNF inhibitor to remain in remission. If they can stop taking the TNF inhibitor without having their symptoms come back, they will be spared the side effects of these medicines. Some studies have shown that people can stay in remission after stopping a TNF inhibitor, but other studies have not confirmed it. Researchers want to see if people with RA in remission on a TNF inhibitor can stay in remission without this medicine. Also there may be a clinical, imaging (MRI, ultrasound), laboratory profile that will help to determine which patients remain in remission after stopping these drugs. Objectives: * To see whether RA remission can continue after discontinuing use of a TNF inhibitor. * To determine if clinical, imaging and immunological measurements can predict which participants will flare and which will remain in remission after discontinuing TNF inhibitor. Eligibility: -Individuals at least 18 years of age who have RA that is being controlled with TNF inhibitors. We plan to randomize 291 patients. Design: * The study has seven visits over about 2 years. Six visits occur in the first year of the study, about 12 weeks apart. The final study visit is 1 year after the end of the treatment phase. * At the first visit, participants will be screened with a physical exam and medical history. They will complete a questionnaire about their RA symptoms. A blood sample will be collected. They will continue to take their RA medicines during this time. * The second visit will repeat tests from the first visit. These tests will confirm that the RA is in remission. Imaging studies will be performed on the hands, wrists, feet, and their connected joints. After this visit, participants will stop taking their TNF inhibitors and will start to have injections of a study drug. This drug will be either the participant's original TNF inhibitor or a placebo. * There will be follow-up visits at weeks 12, 24, and 36. Participants will have a medical history and joint exam. They will also provide blood samples and answer questions about their RA symptoms. * At the sixth visit (week 48), participants will repeat the tests and imaging studies from the second visit. They will stop taking the study injections. * Continued RA treatment after this visit will be decided by the participant and his or her rheumatologist. Participants may take any recommended medicine, including the TNF inhibitor they had been taking before the study. They will also receive a questionnaire to complete at home and mail back before the final study visit. * At the final visit (week 100), participants will repeat the tests and imaging studies from the second and sixth visits.Show More
Waitlist
Phase 4
Est. 5 - 8 Weeks
Florina Constantinescu, MD
Principal Investigator
Guselkumab for Psoriatic Arthritis
Janssen Clinic, Baltimore + 1 more
This trial is testing guselkumab, a medication that reduces inflammation, in patients with psoriatic arthritis affecting the spine. It works by blocking a protein called IL-23 to help reduce symptoms and inflammation. Guselkumab is the first IL-23 specific inhibitor approved for the treatment of moderate-to-severe psoriasis.Show More
Recruiting
Phase 4
Est. 6 - 12 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director
Adalimumab Discontinuation for Uveitis
Research Clinic, Baltimore + 1 more
The proposed study is a stratified, block-randomized, double-masked, controlled trial to determine the feasibility of discontinuing adalimumab treatment in patients with quiescent uveitis associated with juvenile idiopathic arthritis (JIA) or chronic anterior uveitis (CAU).Show More
Waitlist
Phase 4
Est. 3 - 12 Weeks
Nisha Acharya, MD MS
Principal Investigator
Bimekizumab for Psoriatic Arthritis
UCB Biopharma Clinic, Wheaton + 1 more
This trial is testing the safety and effectiveness of bimekizumab, a medication given as an injection under the skin. It is aimed at adults who have psoriatic arthritis, a condition that causes joint pain and swelling. Bimekizumab works by blocking proteins that cause inflammation, helping to reduce pain and swelling.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 6 Weeks
UCB Cares
Study Director
Non-Surgical Interventions for Knee Osteoarthritis
Research Clinic, Bethesda + 3 more
There is an urgent public health need to reduce reliance on opioids for effective long-term pain management, particularly in knee osteoarthritis (KOA). This effectiveness trial will compare commonly recommended treatments to reduce pain and functional limitations in KOA.These results will lead to improved patient selection for treatment and inform evidence based guidelines by offering well-tested, effective, non-surgical alternatives.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 5 - 8 Weeks
Steven Cohen, MD
Principal Investigator
Upadacitinib for Psoriatic Arthritis
AbbVie Clinic, Wheaton + 2 more
The study objectives of Period 1 are to compare the efficacy, safety, and tolerability of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo for the treatment of signs and symptoms in adults with moderately to severely active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to biologic disease-modifying anti-rheumatic drug (bDMARD). The objective of Period 2 is to evaluate the long-term safety, tolerability and efficacy of upadacitinib 15 mg QD and 30 mg QD in participants who have completed Period 1.Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
AbbVie Inc.
Study Director
Risankizumab for Psoriatic Arthritis
AbbVie Clinic, Wheaton + 2 more
The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).
Waitlist
Phase 3
Est. 3 - 12 Weeks
AbbVie Inc.
Study Director
PRP vs Corticosteroid Injections for Shoulder Osteoarthritis
Research Clinic, Bethesda + 1 more
This trial investigates LP-PRP injections for young active duty and civilian patients with shoulder osteoarthritis. The treatment uses concentrated platelets from the patient's own blood to promote healing and reduce inflammation, aiming to improve pain and function without surgery. This method has shown potential in treating various inflammatory and degenerative conditions by modulating the inflammatory environment and promoting tissue repair.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team
Page 1 of 4
Frequently Asked Questions
Explore related conditions